|
|
Neurocrine Biosciences Inc (NASDAQ: NBIX) |
|
Price: $96.1600
$1.27 
1.338%
|
| Day's High:
| $98.52
| Week Perf:
| 0.92 %
|
| Day's Low: |
$ 94.30 |
30 Day Perf: |
-13.76 % |
| Volume (M): |
1,768 |
52 Wk High: |
$ 157.98 |
| Volume (M$): |
$ 169,972 |
52 Wk Avg: |
$129.42 |
| Open: |
$96.88 |
52 Wk Low: |
$84.23 |
|
|
| Market Capitalization (Millions $) |
9,976 |
| Shares
Outstanding (Millions) |
104 |
| Employees |
1,400 |
| Revenues (TTM) (Millions $) |
2,355 |
| Net Income (TTM) (Millions $) |
341 |
| Cash Flow (TTM) (Millions $) |
-18 |
| Capital Exp. (TTM) (Millions $) |
38 |
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc.
is a biopharmaceutical company that is focused on the research, development, and commercialization of treatments for neurological and endocrine-related diseases and disorders.
The company was founded in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences has a strong portfolio of products in various stages of development, including several that have received regulatory approval in the United States and other international markets.
One of its most successful products is Ingrezza, a drug that is used to treat tardive dyskinesia, a condition characterized by involuntary muscle movements.
Ingrezza was approved by the FDA in 2017 and has since become the leading drug in the market for the treatment of tardive dyskinesia.
Neurocrine Biosciences also has several other products in its pipeline, including Ongentys, a drug for the treatment of Parkinsones disease, which was approved by the FDA in 2020.
In addition to its focus on commercializing drugs for neurological and endocrine disorders, Neurocrine Biosciences also invests heavily in research and development.
The company has a strong commitment to discovering and developing new therapies for conditions that have few or no treatment options.
Overall, Neurocrine Biosciences Inc.
is a leading biopharmaceutical company that has been making significant contributions to the field of medicine by developing innovative treatments for neurological and endocrine-related disorders.
With a strong pipeline of products and a commitment to research and development, the company is well-positioned for future growth and success.
Company Address: 6027 Edgewood Bend Court, San Diego, 92130 CA
Company Phone Number: 617-7600 Stock Exchange / Ticker: NASDAQ NBIX
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Neurocrine Biosciences Inc
Neurocrine Biosciences Inc (NBIX) has reported a strong first quarter in 2024, with a significant increase in revenue leading the company to profitability. The biotechnology and pharmaceuticals company saw a revenue increase of 22.574% to $515.30 million, with earnings per share at $0.42 compared to $-0.79 in the same period last year. This marks a 69.37% decrease in earnings per share from the previous quarter, but a slight uptick in revenue from $515.20 million.
The company reported a bottom-line profit of $43.400 million in the first quarter of 2024, a significant improvement from a net loss of $-76.600 million in the same period last year. Neurocrine Biosciences Inc also noted improving profit margins, with a net margin of 8.42% and an operating margin of 19.27% in the first quarter of 2024.
|
| Neurocrine Biosciences Inc
Neurocrine Biosciences Inc has shown impressive growth in their most recent fiscal period, with both income and revenue seeing significant increases year on year. Income jumped by 61.33% to $1.37 per share, while revenue increased by 25.049% to $515.20 million. This growth outpaced many of their peers in the Biotechnology & Pharmaceuticals industry, where the average revenue growth was just 9.77% in the fourth quarter of 2023 compared to the same period a year before.
The company has also seen strong sequential growth, with earnings per share soaring by 67.24% from $0.82 per share and revenue growing by 3.288% from $498.80 million. Net earnings for the fiscal interval ending December 31, 2023 increased by 65.96% to $147.700 million compared to the same period a year ago. Neurocrine Biosciences Inc has highlighted their improving profit margins, with net margin rising to 28.67% and operating margin edging up to 29.17%.
|
| Neurocrine Biosciences Inc
Neurocrine Biosciences Inc, a biotechnology company trading on the NASDAQ, has experienced a decline in its stock price over the past 5 trading days. With a decrease of -2.28%, the year-to-date performance stands at -10.13%. However, despite this recent decline, the stock is still performing reasonably well, currently trading 1.6% above its 52-week average.
During the most recent fiscal period, Neurocrine Biosciences Inc saw a significant increase in its revenue. Revenue grew by a remarkable 28.59% to reach $498.80 million. The company also witnessed a rise in income, which grew by 18.84% to $0.82 per share. Both the revenue and income figures surpassed the numbers reported in the comparable period from the previous year. In contrast, earnings per share (EPS) fell by -13.68% from $0.95 per share in the previous financial reporting period. Despite this decline, revenue advanced by 10.183% from $452.70 million.
|
| Neurocrine Biosciences Inc
Neurocrine Biosciences Inc (NBIX) has shown impressive financial results for the interval closing June 30, 2023, marking a significant turnaround. The company has displayed a positive Income per Share of $0.95 compared to a negative $0.18 per share the previous year, while earnings per share have also turned positive, increasing from a negative $0.79 per share in the preceding reporting season. Additionally, revenue has soared by a considerable 19.699% to $452.70 million from $378.20 million compared to the same reporting season a year ago, and sequentially, there has been a 7.683% advancement from $420.40 million.
This performance sets NBIX apart from its peers in the Biotechnology & Pharmaceuticals industry, as many of them are currently experiencing a decline in top-line revenue. NBIX's revenue growth shows its resilience and ability to thrive despite challenging industry conditions. Furthermore, the company has reported a net income of $95.500 million in the financial interval closing June 30, 2023, a significant improvement from a net deficit of $-16.900 million during the same reporting season a year ago.
|
| Neurocrine Biosciences Inc
The stock market has been buzzing with excitement over the recent announcement from Neurocrine Biosciences Inc. As we head into the second quarter of 2023, the company has reported a return on equity of 4.02%, which outperforms their previous average of -4.05%. This is certainly a promising result for investors and stakeholders alike.
While the decreasing net income may have led to a slight drop in ROE relative to the previous quarter, it is worth noting that Neurocrine Biosciences Inc is still performing well within the biotechnology and pharmaceutical industry. While there were nine companies that had a higher return on equity, the overall ranking of Neurocrine Biosciences Inc has advanced in the quarter, moving from 1787 to 1486.
|
| Per Share |
Current |
| Earnings (TTM) |
3.26 $ |
| Revenues (TTM) |
22.7 $
|
| Cash Flow (TTM) |
- |
| Cash |
10.37 $
|
| Book Value |
24.96 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
3.26 $
|
| Revenues (TTM) |
22.7 $ |
| Cash Flow (TTM) |
- |
| Cash |
10.37 $
|
| Book Value |
24.96 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
4.59% 